Adoptive T Cell Therapy

Adoptive T cell therapy has the potential to increase antitumor immunity, enhance vaccine efficacy, and limit graft-versus-host disease (GVHD). Recent advances in protein engineering and molecular biology have increased the feasibility of using genetically engineered T cells to treat disease, leading to an influx of new discoveries and techniques.

Cambridge Healthtech Institute's Inaugural Adoptive T Cell Therapy will review the latest strategies for target discovery, vector selection, and chimeric antigen receptors (CAR) against tumor antigens. Experts will discuss techniques for increasing specificity, choosing domains, and incorporating fusion proteins into T cells.

Dosing uncertainties such as toxicity threshold and antigen detection will also be addressed. Overall, this inaugural event will focus on issues facing the field with an emphasis on engineered T cells and the use of adoptive t cell transfer to facilitate therapeutic treatments for cancer, infectious diseases, and bone marrow transplants.